advertisement
Abstract #12293 Published in IGR 7-2
The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a β-blocker in patients with glaucoma
Tsukamoto H; Noma H; Matsuyama S; Ikeda H; Mishima HKJournal of Ocular Pharmacology and Therapeutics 2005; 21: 170-173
PURPOSE: Brinzolamide and dorzolamide are often used as adjunctive therapy to other antiglaucoma agents. The purpose of this study was to compare the efficacy and safety of brinzolamide 1% versus dorzolamide 1% when added to the combination therapy of latanoprost and a β-blocker in patients with glaucoma. METHODS: An 8-week, randomized, open-label comparative study was performed in 52 patients with glaucoma. Brinzolamide 1% (twice a day) or dorzolamide 1% (3 times a day) was randomly administered to the patients who had been treated with both latanoprost and a β-blocker. RESULTS: Intraocular pressure (IOP) were both decreased significantly (P < 0.0001) from 18.6 ± 2.3 mmHg to 16.7 ± 2.3 mmHg and from 18.4 ± 2.6 mmHg to 16.6 ± 2.5 mmHg, respectively, 8 weeks after the addition of brinzolamide or dorzolamide. However, the difference between the groups was not significant (P = 0.86). The incidence of ocular irritation was significantly higher (P < 0.0001) in the dorzolamide group (74%) than the brinzolamide group (16%), but there was no significant difference in blurred vision between the groups (dorzolamide 37% versus brinzolamide 52%, P = 0.40). CONCLUSIONS: We concluded that the efficacy of brinzolamide 1% was equivalent to dorzolamide 1%; however, the safety of brinzolamide 1% was superior to dorzolamide 1% as adjunctive therapy to the combination with latanoprost and a β-blocker.
Dr. H. Tsukamoto, Dept. of Ophthalmol. and Vis. Sci., Hiroshima Univ. Grad. Sch. B. S., 1-2-3 Kasumi, Minami-Ku Hiroshima 734-8551, Japan
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
